This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Toxic Stocks to Discard From Your Portfolio Right Now
by Rimmi Singhi
If you own a toxic stock for long, you are likely to see a big loss in your wealth. Discarding them at the right time is the key to shield your portfolio from big losses.
Company News for Aug 10, 2020
by Zacks Equity Research
Companies In The News Are: ILMN, TTD, EOG, TMUS.
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.
Illumina (ILMN) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of -13.89% and -6.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Illumina (ILMN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.
BMY vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. ILMN: Which Stock Is the Better Value Option?
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Illumina Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.
Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus
by Debanjana Dey
Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
Illumina Takes Over BlueBee, Fortifies NGS Data Processing
by Zacks Equity Research
With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.
Top Research Reports for Netflix, Bristol-Myers & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Bristol-Myers Squibb (BMY) and NextEra Energy (NEE).
GILD vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod
by Zacks Equity Research
Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.
Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA
by Zacks Equity Research
Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.
Myriad Genetics' Test Better Predicts Drug Levels Per Study
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.
Medtronic's StealthStation Feature Recall Classified Class I
by Zacks Equity Research
This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.
Globus Medical Faces Business Loss Amid Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.
Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.
Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy
by Zacks Equity Research
Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.
IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test
by Zacks Equity Research
This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.
Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.
Here's Why You Should Hold on to Haemonetics Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.